ER-Alpha36 Mediates Non-Genomic Estrogen and Anti-Estrogen Signaling in Breast Cancer Cells
نویسندگان
چکیده
Estrogen signaling is essential in the initiation and development of neoplasia in mammary gland. In the past several decades, extensive efforts have been dedicated to understand the underlying mechanisms of this important signaling pathway in mammary carcinogenesis, which have facilitated the development of anti-estrogen therapy, the first targeted therapy for human cancer. It has been well documented that the diverse activities of estrogens and anti-estrogens are mediated by specific receptors designated as estrogen receptors (ERs). Currently, there are two identified ERs, ER- and ER-, both of which are ligand-activated transcription factors that stimulate target gene transcription. Compelling evidence indicates that estrogens, especially 17-estradiol (E2), up-regulate the expression and function of c-Myc and cyclin D1, activate cyclin E-Cdk2 complexes and promotes cell cycle progression from G1 to S phase in mammary epithelial cells. Thus, stimulation of target gene expression by ERs in response to estrogens is prevailingly thought to be responsible for estrogen-stimulated mammary carcinoma initiation and progression. Despite the clarity with which ERs have been shown to act as ligand-dependent transcription factors, it became apparent now that not all of the activities mediated by ERs are accomplished through a direct effect on gene transcription. Another signaling pathway (also known as a non-classic, non-genomic, extra-nuclear or membrane-initiated signaling pathway) exists that involves cytoplasmic signaling proteins, growth factor receptors and other membrane-initiated signaling pathways. Several intracellular signaling pathways have been shown cross-talking with the membrane-initiated estrogen signaling: the adenylate cyclase pathway, the phospholipase C pathway, the G-protein-coupled receptor-activated pathways, the PI3K/AKT and the MAPK pathways. Currently, the identity of the membrane-based estrogen receptor that mediates non-genomic estrogen effects has not been fully established. ER-, two forms of ER-, full-length (66-kDa) and short form (46-kDa) have been found on or near the plasma membrane and mediates membrane-initiated estrogen signaling. In addition, there is also evidence indicating that GPR30, an orphan G-protein-coupled-receptor, mediates the rapid, non-genomic responses to estrogens. In 2005, our laboratory identified and cloned a novel variant of ER-, which
منابع مشابه
ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
BACKGROUND Recently, a novel variant of ER-alpha, ER-alpha36 was identified and cloned. ER-alpha36 lacks intrinsic transcription activity and mainly mediates nongenomic estrogen signaling. Here, we studied the role of nongenomic estrogen signaling pathways mediated by ER-alpha36 in tamoxifen resistance and agonist action. METHODOLOGY The cellular localization of ER-alpha36 was examined by imm...
متن کاملGenetic polymorphisms in the estrogen receptor - α Gene codon 325(CCC}CCG) and risk of breast cancer among Iranian women: a case control study
Abstract Background: The Iranian breast cancer patients are relatively younger than their Western counterparts. Evidence suggests that alterations in estrogen signaling pathways , including estrogen receptor-α (ER- α ), occur during breast cancer development in Caucasians. Epidemiologic studies have revealed that age-incidence patterns of breast cancer in Asians differ from those in Cauca...
متن کاملBioinformatics-Based Prediction of FUT8 as a Therapeutic Target in Estrogen Receptor-Positive Breast Cancer
Abstract Introduction: Estrogen receptor-positive (ER-positive) breast cancer is a subgroup of breast tumors that is more likely to respond to hormone therapy. ER-positive and ER- negative breast cancers tend to show different patterns of metastasis because of different signaling cascade and genes that are activated by estrogen response. Genetic factors can contribute to high rates of metastas...
متن کاملBioinformatics-Based Prediction of FUT8 as a Therapeutic Target in Estrogen Receptor-Positive Breast Cancer
Abstract Introduction: Estrogen receptor-positive (ER-positive) breast cancer is a subgroup of breast tumors that is more likely to respond to hormone therapy. ER-positive and ER- negative breast cancers tend to show different patterns of metastasis because of different signaling cascade and genes that are activated by estrogen response. Genetic factors can contribute to high rates of metastas...
متن کاملOpposite regulation of estrogen receptor-α and its variant ER-α36 by the Wilms' tumor suppressor WT1.
The genomic and non-genomic signaling pathways are well-known estrogen signaling pathways. The 66-kDa estrogen receptor-α (ER-α66) is a typical ligand-inducible transcription factor that mainly mediates genomic estrogen signaling. Recently, we identified and cloned a 36-kDa variant of ER-α66, known as ER-α36. This variant lacks intrinsic transcription activity and predominantly mediates non-gen...
متن کامل